glp-1 diarrhea and vomiting Managing Side Effects of Receptor Agonists – Transformation Weight Control Rx Trends: Real-World Data on

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone

World J Gastroenterology

In addition, ROS production was increased in the heart of HF patients ( Methylglyoxal (MG) is a precursor of advanced glycation end-products (AGEs) and is a major source of intracellular AGEs

The past two years have seen unprecedented momentum: GLP-1 therapies moved from niche to mainstream, supply issues arose then abated, and asset pipelines expanded beyond weight loss to whole-body medications

utilization surged, highlighting North Americas influence on global supply decisions